The company is substantially advanced its development of the novel solution for amyloid heart disease, employing Attruby. Early clinical data indicates promising improvements for those diagnosed by the debilitating illness. The emphasis underscores BridgeBio's dedication to treating unmet patient demands in the cardiology field. Attruby: BridgeBio